1. Mulders MN et al. Global Measles and Rubella Laboratory Network support for elimination goals, 2010-2015. MMWR Morbidity and Mortality Weekly Report, 2016, 65:438-442.
  2. Riddell MA et al. Laboratory testing and confirmation of suspected measles infection crucial in countries that have eliminated measles. Annals of Emergency Medicine, 2009, 54:639-640.
  3. Dietz V et al. The laboratory confirmation of suspected measles cases in settings of low measles transmission: conclusions from the experience in the Americas. Bulletin of the World Health Organization, 2004, 82:852-857.
  4. Bolotin S et al. The utility of measles and rubella IgM serology in an elimination setting, Ontario, Canada, 2009-2014. PLOS One, 2017, Aug 29;12(8):e0181172.
  5. Mercader et al. Measles virus IgG avidity assay for use in classification of measles vaccine failure in measles elimination settings. Clinical and Vaccine Immunology, 2012, ;19(11);1810-1816.
  6. Santibanez et al. Measles virus spread initiated at international mass gatherings in Europe, 2011. EuroSurveillance, 2014, 19(35):pii=20891.
  7. Rota JS et al. Two case studies of modified measles in vaccinated physicians exposed to primary measles cases: high risk of infection but low risk of transmission. Journal of Infectious Disease, 2011, 204; Suppl 1:S559-563.
  8. Rosen JB et al. Outbreak of measles among persons with prior evidence of immunity, New York City, 2011. Clinical Infectious Disease, 2014, 58:1205-1209.
  9. Sowers SB et al. High concentrations of measles neutralizing antibodies and high-avidity measles IgG accurately identify measles reinfection cases. Clinical Vaccine Immunology, 2016, 23:707-716.
  10. Hahné SJM et al. Measles outbreak among previously immunized health care workers, the Netherlands, 2014. Journal of Infectious Diseases, 2016, 214 (15 december):1980-1986.
  11. Roy F et al. Rapid identification of measles virus vaccine genotype by real-time PCR. Journal of Clinical Microbiology, 2017, 55 (3): 735-743.
  12. WHO. Monitoring progress towards measles elimination. Weekly Epidemiological Record, 2010, 49 (85):490-495.
  13. Durrheim DN et al. Measles - The epidemiology of elimination. Vaccine, 2014, 32:6880-6883.
  14. Ammari LK et al. Secondary measles vaccine failure in healthcare workers exposed to infected patients. Infection Control and Hospital Epidemiology, 1993, 14(2):81-86.
  15. Vainio K et al. Measles virus genotyping an important tool in measles outbreak investigation in Norway, 2011. EuroSurveillance, 2012, 17(50):pii=20340.
  16. de Oliviera SA et al. Atypical measles in a patient twice vaccinated against measles: transmission from as unvaccinated household contact. Vaccine, 2001, 19:1093-1096.
  17. Oliveira SA et al. Use of RT-PCR on oral fluid samples to assist the identification of measles cases during an outbreak. Epidemiology and Infection, 2003, 130:101-106.
  18. Cohen BJ et al. Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. Vaccine, 2007, 26(1):59-66.